Comparison of amino acid radiotracers L-[methyl-¹¹ C]methionine and О-2-[¹⁸F]fluoroethyl-L-tyrosine for PET/CT imaging of cerebral gliomas

Introduction. The radiotracer L-[methyl-¹¹C]methionine (Met) has long been considered the tracer of choice in CNS tumors diagnosis using positron emission tomography, combined with computed tomography (PET/CT). However, there are more and more logistic arguments for the introduction of fluorinated amino acids into diagnostics, in particular, O-2-[¹⁸F]fluoroethyl-L-tyrosine (FET), for which our institute has developed its own method of radiochemical synthesis. The aim of the study was to compare amino acid radiotracers L-[methyl-¹¹C]methionine (Met) and O-2-[¹⁸F]fluoroethyl-L-tyrosine (FET) in the imaging of cerebral gliomasusing PET/CT. Materials and methods. PET/CT studies using Met and FET were performed in 36 patients (15 men and 21 women) aged 28 to 73 years with suspected intracerebral tumor before surgery of biopsy. Pathohistologicalstudy verified gliomas(n-31) or other tumors (n=3), inflammatory process (n=2). The analysis of results included visual comparison of images, calculation of the tumor-to-brainratio (TBR) and metabolic tumor volume for Met and PET. Results. Visual and quantitative analysis of the scans revealed that tumor uptake pattern of FET was similar to those of Met. No significant differences were found in the TBR of both radiotracers in tumors of different grades of malignancy. A strong significant correlation (r=0,9) was revealed between the TBR of Met and FET in gliomas. There were no significant differences between tumor metabolic volumes when using the same cutoff values for both radiotracers. The ROC analysis established the same diagnostic value of Met and FET in differentiating low and high grade gliomas (area under curve 0,884 and 0,881, respectively). Conclusion. Amino acid radiotracers provide comparable diagnostic information in preoperative imaging of gliomas using PET/CT, which makes it possible to recommend FET as an adequate alternative to Met for PET centers without on-site cyclotron.

1. Galldiks N., Langen K.J., Pope W.B. What is the status quo of positron emission tomography in patients with brain tumors // Neuro-Oncology. 2015. Vol. 17, No. 11. P. 1334-1444. doi: 10.1093/neuonc/nov118.

2. Law I., Albert N.I., Arbizu J., Boellaard R., Drzezga A., Galldiks N., Fougere C., Langen K-J., Lopci E., Lowe V., McConathy J., Quick H.H., Sattler B., Schuster D.M., Tonn J-C., Weller M. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0 // Eur. J. Nucl. Med. Mol. Imaging. 2019. Vol. 46. P. 540-557. doi: 10.1007/s00259-018-4207-9.

3. Gomzina N.A., Kuznetsova O.F. L-[Methyl-[11C]]-methionine of high enantiomeric purity production via online-11C-methylation of L-homocysteine thiolactone hydrochloride // Russ. J. Bioorg. Chem. 2011. Vol. 37, No. 2. P. 191-197.

4. Krasikova R.N., Kuznetsova O.F., Fedorova O.S. No carrier added synthesis of O-(2'-[18F]fluoroethyl)-L-tyrosine via a novel type of chiral enantiomerically pure precursor, NiII complex of a (S)-tyrosine Schiff base // Bioorg. Med. Chem. 2008. Vol. 16. P. 4994-5003.

5. Orlovskaya V., Fedorova O., Nadporojskii M., Krasikova R. A fully automated azeotropic drying free synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) using tetrabutylammoniumtosylate // Appl. Radiat. Isot. 2019. Vol. 152. P. 135-139. doi: 10.1016/j.apradiso.2019.07.006.

6. Weber W.A., Wester H.J., Grosu A.L., Grosu A.L., Herz M., Dzewas B., Feidmann H-J., Molls M., Stocklin G., Schweiger M. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study // Eur. J. Nucl. Med. 2000. Vol. 27. P. 542-549.

7. Grosu A.L., Astner S.T., Riedel E., Nieder C., Wiedenmann N., Heinemann F., Schwaiger M., Molls M., Wester H-J., Weber W.A. Aninterindividual comparison of O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET)-and L-[Methyl- (11)C]Methionine (MET)-PET in patients with brain gliomas and metastases // Int. J. Radiat. Oncol. Biol. Phys. 2011. Vol. 81. P. 10491058. doi: 10.1016/j.ijrobp.2010.07.002.

8. Langen K.J., Stoffels G., Filss K.,Heinzel A., Stegmayr C., Lohmann P. et al. Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[18F]fluoroethyl)-L-tyrosine (FET) // Methods. 2017. Vol. 130. P. 124-134. doi: 10.1016/j.ymeth.2017.05.019.

9. Okubo S., Zhen H.N., Kawai N., Nishiyama Y., Haba R., Tamiya T. Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas // J. Neurooncol. 2010. Vol. 99, No. 2. Р. 217-225. doi: 10.1007/s11060-010-0117-9.

10. Rau F.C., Weber W.A., Wester H.J., Herz M., Becker I., Kruger A., Achwaiger M., Senekowitsch-Schmidtke R. O-(2-[18F]fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes // Eur. J. Nucl. Med. Mol. Imaging. 2002. Vol. 29. P. 1039-1046. doi: 10.1007/s00259-002-0821-6.

11. Fedorova O.S., Kuznetsova O.F., Shatik S.V., Stepanova M.A., Belokon' Iu.N., Maleev V.I., KrasikovaR.N. (18)F-labeled tyrosine derivatives: synthesis and experimental studies on accumulation in tumors and abscesses // Bioorg Khim. 2009. Vol. 35, No. 3. P. 334-343. doi: 10.1134/s1068162009030042.

12. Pauleit D., Stoffels G., Schaden W., Hamacher K., Bauer D.,Tellmann L., Herzog H.,Broer S., Coenen H., Langen K.J. PET with O-(2-[18F]fluo-roethyl)-L-tyrosine (FET) in peripheral tumors: first clinical results // J. Nucl. Med. 2005. Vol. 46. P. 411-416.

13. Floeth F.W., Pauleit D., Sabel M., Reifenberger G., Stoffels G., Stummer W., Rommel F., Hamacher K., Langen K.J. 18F-FET PET differentiation of ringenhancing brain lesions // J. Nucl. Med. 2006. Vol. 47, No. 5. P. 776-782.

14. Hutterer M., Bumes E., Riemenschneider M.J., Grosse J., Hellwig D., Galldiks N., Langen K.J., Hau P. AIDS-related central nervous system toxoplasmosis with increased 18F-fluoroethyl-L-tyrosine amino acid PET uptake due to LAT1/2 expression of inflammatory Cells // Clin. Nucl. Med. 2017. Vol. 42, No. 12. P. e506-e508. doi: 10.1097/RLU.0000000000001873.

15. Salber D., Stoffels G., Pauleit D., Reifenberger G., Sabel M., Shah N.J., Hamacher K., Coenen H.H., Langen K.J. // Nucl. Med. Biol. 2006. Vol. 33, P. 1029-1035. doi: 10.1016/j.nucmedbio.2006.09.004.